Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.
Live Science on MSN
'This is a completely different level of anti-vaccine engagement than we've ever seen before,' says epidemiologist Dr. Seth Berkley
Epidemiologist Dr. Seth Berkley spoke to Live Science about the importance of vaccine equity and the obstacles undermining it ...
This insightful review explores key areas of cancer genetic research, focusing on genes that may benefit from ...
Robert Dowd, CSC, during which McElroy offered his thoughts on ways to address political polarization in America. The event ...
GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Ladies and gentlemen, a very warm welcome to the GSK Q3 2025 Results Call. I'm delighted to be joined today by Emma Walmsley, Luke ...
Novartis AG ( NYSE: NVS) M&A Call October 27, 2025 8:00 AM EDT ...
Despite several therapeutic strategies having been developed, cancer is still one of the leading causes of mortality ...
President Donald Trump’s physician, Dr. Sean P. Barbabella, announced that after conducting a battery of tests, he found that ...
CoV-2, has led to the first approval of mRNA vaccines in humans. By producing the full-length SARS-CoV-2 Spike protein, they ...
Our sex experts weigh in on how to have mind-blowing sex with an older queer woman. Our culture tends to be youth-obsessed, ...
INGREZZA net product sales for the third-quarter 2025 were $687 million, reflecting 10% sequential growth over the second quarter of 2025 and 12% growth year-over-year. Double-digit volume growth was ...
Nutcracker Therapeutics is driving down costs, accelerating speed of processing and improving scalability with an end-to-end, GMP-grade production process. Healthcare is on the cusp of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback